Cure My Disease

Don't miss your cure!

 Log in / Sign up

Million-Person quest to catch a silent cancer early

NCT ID NCT06787456

Diagnosis Sponsor: Ming-Yuan Chen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This study aims to build a massive screening cohort of one million people to improve early detection of nasopharyngeal carcinoma, a cancer linked to Epstein-Barr virus (EBV). Participants aged 30 to 69 will provide blood, saliva, and nasal brush samples for EBV antibody and DNA tests, along with lifestyle and health information. Researchers will track who develops the cancer to see which tests best predict it, potentially leading to a standard screening program.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EBV antibody and DNA tests, plus epidemiological surveys and clinical exams
What this could lead to
If successful, this could establish a reliable screening method for nasopharyngeal carcinoma, enabling earlier detection and better outcomes.
What could go wrong
The study is observational and very large, so results may take years. The tests may not be accurate enough for widespread use, and false positives could cause unnecessary anxiety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2045

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Residents with a definite native place, aged 30 and 69 years at screening, and capable of long-term cooperation with screening and follow-up.

Ages

30 to 69 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Residents with a definite native place; * Aged 30 and 69 years at screening; * Capable of long-term cooperation with screening and follow-up. Exclusion Criteria: * Known severe cardiovascular, liver or kidney disease, or neuropsychiatric disorders; * History of previous malignant tumors; * Severe autoimmune diseases or immunodeficiency; * Females with a positive pregnancy test at screening; * Inability to cooperate with the study due to psychological, social, family, and geographical reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasopharyngeal carcinoma (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasopharyngeal carcinoma (NPC) Screening

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Fifth Affiliated Hospital of Sun Yat-sen University

    RECRUITING

    Zhuhai, Guangdong, 519000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.